Skip to main navigation
Day One Bio
  • Our Company
    • About Us
    • Leadership
    • Partnering
    • Contact
  • Our Pipeline
    • Development Overview
    • Tovorafenib
    • Pimasertib
    • Clinical Trials
    • Expanded Access
    • Publications & Posters
  • Join Our Team
    • Career Opportunities
    • Our Culture
    • Diversity & Inclusion
  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
      • Annual Reports & Proxy
      • Quarterly Results
    • Corporate Governance
      • Governance Documents
      • Leadership
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Request Information
  • Patients & Families
  • Patients & Families
Select Page
Investors & Media

Event Details

Investors & Media

Event Details

2022 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 18, 2022

Supporting Materials

FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors 953.4 KB
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration 481.7 KB
Investor Contact

LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com

Media Contact

Laura Cooper
Media@dayonebio.com

Helpful Tools
  • Print Page
  • Email Alerts
  • RSS Feed
Footer logo
Our Company
  • About Us
  • Leadership
  • Partnering
  • Contact
Our Pipeline
  • Development Overview
  • Tovorafenib
  • Pimasertib
  • Clinical Trials
  • Expanded Access
  • Publications & Posters
Join Our Team
  • Career Opportunities
  • Our Culture
  • Diversity & Inclusion
Investors & Media
  • Company Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Investor Resources
logo
© 2023 Day One Biopharmaceuticals, Inc.
  • Privacy Policy
  • Terms of Use